Quantitative assessment of hepatic fibrosis in chronic hepatitis B and C: T1 mapping on Gd-EOB-DTPA-enhanced liver magnetic resonance imaging

Table 1 Patients’ characteristics n %

Characteristic	No fibrosis,n = 23	Liver fibrosis,n = 50	All,n = 73
Age in yr	39.5 ± 11.1	41.3 ± 12.5	40.8 ± 12.1
Sex
Male	17 (74)	30 (60)	47 (64)
Female	6 (26)	20 (40)	26 (36)
Height in m	1.72 ± 0.09	1.70 ± 1.21	1.71 ± 1.15
Weight in kg	77.21 ± 17.32	78.23 ± 16.12	78.10 ± 16.64
BMI in kg/m2	24.09 ± 4.91	22.06 ± 4.57	23.73 ± 4.65
CHB	21 (34)	41 (66)	62 (85)
CHC	2 (18)	9 (82)	11 (15)

Data are presented as n (%) or mean ± SD. BMI: Body mass index; CHB: Chronic hepatitis B; CHC: Chronic hepatitis C.

Table 2 Pre, Post, reduction rate of T1 relaxation time, and hepatocyte fraction (%) of patients at different METAVIR fibrosis stages

Fibrosis stage, (METAVIR)	F0, n = 23	F1, n = 19	F2, n = 13	F3, n = 6	F4, n = 12	Total, n = 73
Mean pre-T1 liver	180 ± 28	188 ± 19	174 ± 17	192 ± 22	200 ± 24	186 ± 24
Mean post-T1 liver	356 ± 44	355 ± 38	316 ± 34	336 ± 43	305 ± 50	338 ± 46
RE	0.94 ± 0.18	0.89 ± 0.20	0.94 ± 0.16	0.71 ± 0.17	0.52 ± 0.15	0.84 ± 0.23
HeF (%)	88.77 ± 5.10	84.23 ± 6.99	79.71 ± 8.09	70.90 ± 7.27	62.80 ± 7.01	80.24 ± 11.30

Data are presented as mean ± SD. HeF: Hepatocyte fraction; RE: Reduction rate of T1 relaxation time.

Table 3 Correlation of reduction rate of T1 relaxation time, hepatocyte fraction, and METAVIR fibrosis stages

	Pre	Post	RE	HeF
r (95%CI)	0.188 (-0.045 to 0.4003)	-0.525 (-0.674 to 0.336)	-0.773 (-0.852 to 0.661)	-0.808 (-0.875 to 0.709)
P value	0.112	0.001	< 0.001	< 0.001

HeF: Hepatocyte fraction; RE: Reduction rate of T1 relaxation time.

Table 4 Performance of the mean reduction rate of T1 relaxation time and hepatocyte fraction for the prediction of METAVIR fibrosis stages according to cut-off values

Parameters	≥ F1	≥ F2	≥ F3	= F4
Cut-off
HeF (%)	82.93	79.24	74.37	74.37
RE	0.75	0.73	0.72	0.72
AUC
HeF (%)	0.837 (0.733-0.913)	0.890 (0.795-0.951)	0.957 (0.881-0.990)	0.957 (0.882-0.991)
RE	0.678 (0.559-0.783)	0.723 (0.606-0.821)	0.921 (0.834-0.971)	0.962 (0.889-0.993)
Sensitivity, %
HeF(%)	72.0 (57.5-83.8)	77.4 (58.9-90.4)	94.4 (72.7-99.9)	100.0 (73.5-100.0)
RE	44.0 (30.0-58.7)	58.1 (39.1-75.5)	88.9 (65.3-98.6)	100.0 (73.5-100.0)
Specificity, %
HeF (%)	82.6 (61.2-95.0)	92.9 (80.5-98.5)	92.7 (82.4-98.0)	85.3 (73.8-93.0)
RE	100.0 (85.2-100.0)	92.9 (80.5-98.5)	92.7 (82.4-98.0)	86.9 (75.8-94.2)
PPV, %
HeF (%)	90.0 (76.3-97.2)	88.9 (70.8-97.6)	81.0 (58.1-94.6)	57.1 (34.0-78.2)
RE	100.0 (84.6-100.0)	85.7 (63.7-97.0)	80.0 (56.3-94.3)	60.0 (36.1-80.9)
NPV, %
HeF (%)	57.6 (39.2-74.5)	84.8 (71.1-93.7)	98.1 (89.7-100.0)	100.0 (93.2-100.0)
RE	45.1 (31.1-59.7)	75.0 (61.1-86.0)	96.2 (87.0-99.5)	100.0 (93.3-100.0)
PLR
HeF (%)	4.14 (1.7-10.3)	10.84 (3.6-32.8)	12.99 (5.0-33.6)	6.78 (3.7-12.4)
RE	_	8.13 (2.6-25.2)	12.22 (4.7-31.8)	7.62 (4.0-14.5)
NLR
HeF (%)	0.34 (0.2-0.5)	0.24 (0.1-0.5)	0.060 (0.009-0.4)	_
RE	0.56 (0.4-0.7)	0.45 (0.3-0.7)	0.12 (0.03-0.4)	_

AUC: Area under the curve; HeF: Hepatocyte fraction; NLR: Negative likelihood ratio; NPV: Negative predictive value; PLR: Positive likelihood ratio; PPV: Positive predictive value; RE: Reduction rate of T1 relaxation time.